Rosa Elena Lozano-Morales

No ORCID on file · 2 papers in corpus

article 2017

Danazol as First-Line Therapy for Myelodysplastic Syndrome

·doi:10.1016/j.clml.2017.11.007

BackgroundAllogeneic stem cell transplantation (ASCT) represents the only option with a potential cure rate of 30% to 50% in myelodysplastic syndrome (MDS); however, < 5% of patients are optimal candidates for this management. Therapeutic o…

article 2016

Danazol As First-Line Therapy for Myelodysplastic Syndromes

·doi:10.1182/blood.v128.22.5528.5528

Abstract Introduction: Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematological disorders characterized by ineffective hematopoiesis and variable degrees of peripheral cytopenias. Neither curative nor standard thera…